Therapies that specifically target HER2 include Herceptin (trastuzumab), Perjeta (pertuzumab), and T-DM1 (trastuzumab emtansine) which is sold under the brand name Kadcycla. Treatment of early ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

These ready-made antibodies inhibit the binding of the drug to its target, human epidermal growth factor 2 (HER2), enabling researchers to develop highly selective and sensitive assays for bioanalysis ...

The Perjeta-based regimen should be administered for one year as part of a complete regimen for eBC and regardless of the timing of surgery. HER2-positive breast cancer affects almost 100,000 ...

Perjeta has previously been recommended by NICE for NHS use in treating early HER2-positive breast cancer before surgery, i.e. neo-adjuvant use, as well as for HER2-positive breast cancer that has ...

Mridula George, MD, assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, and associate program director for breast medical oncology program in the division of medical ...

For anti-HER2 therapy, 97.3% received a combination of trastuzumab and pertuzumab. For endocrine therapy, 90.9% received an aromatase inhibitor. Metzger and colleagues found that median ...

Perjeta pertuzumab is employed to treat HER2-positive breast cancer by targeting the HER2 receptor and is typically combined with trastuzumab and chemotherapy to enhance treatment outcomes.